Float Short %

4.33

Margin Of Safety %

Put/Call OI Ratio

0.22

EPS Next Q Diff

-0.04

EPS Last/This Y

0.24

EPS This/Next Y

-0.01

Price

Target Price

10.3

Analyst Recom

1.62

Performance Q

-20.47

Relative Volume

0.31

Beta

1.47

Ticker: IFRX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	IFRX	1.12	0.05	27.36	10543
2025-12-29	IFRX	1.015	0.08	0.00	10831
2025-12-30	IFRX	1.02	0.08	0.00	10832
2025-12-31	IFRX	1.015	0.08	0.08	10786
2026-01-02	IFRX	1.095	0.08	22.00	10786
2026-01-05	IFRX	1.15	0.08	0.00	10787
2026-01-06	IFRX	1.175	0.08	0.00	10813
2026-01-07	IFRX	1.21	0.08	0.00	11039
2026-01-08	IFRX	1.1	0.08	0.00	11190
2026-01-09	IFRX	1.05	0.08	3.05	11190
2026-01-12	IFRX	1.025	0.08	226.00	11256
2026-01-13	IFRX	1.015	0.09	43.50	11329
2026-01-14	IFRX	1.065	0.10	592.00	11413
2026-01-15	IFRX	1	0.14	999.99	11855
2026-01-16	IFRX	1.02	0.14	0.20	11845
2026-01-20	IFRX	0.9748	0.11	0.07	3059
2026-01-21	IFRX	1.01	0.11	22.20	3311
2026-01-22	IFRX	1.025	0.22	0.00	3652
2026-01-23	IFRX	1.01	0.22	0.00	3705
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	IFRX	1.12	-71.9	-16.1	-0.67
2025-12-29	IFRX	1.01	-71.9	-1.7	-0.67
2025-12-30	IFRX	1.02	-71.9	-21.4	-0.67
2025-12-31	IFRX	1.02	-71.9	-17.7	-0.67
2026-01-02	IFRX	1.09	-71.9	-39.3	-0.67
2026-01-05	IFRX	1.15	-71.9	-29.3	-0.67
2026-01-06	IFRX	1.17	-71.9	-20.4	-0.67
2026-01-07	IFRX	1.21	-71.9	-22.5	-0.67
2026-01-08	IFRX	1.10	-71.9	-3.6	-0.67
2026-01-09	IFRX	1.05	-71.9	-9.7	-0.67
2026-01-12	IFRX	1.02	-71.9	-13.6	-0.67
2026-01-13	IFRX	1.01	-71.9	-16.4	-0.67
2026-01-14	IFRX	1.07	-71.9	-32.8	-0.67
2026-01-15	IFRX	1.00	-71.9	-2.6	-0.67
2026-01-16	IFRX	1.01	-82.5	-19.3	-0.67
2026-01-20	IFRX	0.98	-82.5	-9.4	-0.67
2026-01-21	IFRX	1.01	-82.5	-29.5	-0.67
2026-01-22	IFRX	1.03	-82.5	-28.0	-0.67
2026-01-23	IFRX	1.00	-82.5	-8.9	-0.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	IFRX	0.00	3.64	4.37
2025-12-29	IFRX	0.00	3.64	4.37
2025-12-30	IFRX	0.00	3.64	4.37
2025-12-31	IFRX	0.00	3.64	4.37
2026-01-02	IFRX	0.00	3.64	4.37
2026-01-05	IFRX	0.00	3.64	4.37
2026-01-06	IFRX	0.00	3.64	4.37
2026-01-07	IFRX	0.00	3.64	4.37
2026-01-08	IFRX	0.00	3.64	4.37
2026-01-09	IFRX	0.00	3.64	4.37
2026-01-12	IFRX	0.00	3.64	4.37
2026-01-13	IFRX	0.00	3.64	4.33
2026-01-14	IFRX	0.00	3.64	4.33
2026-01-15	IFRX	0.00	3.64	4.33
2026-01-16	IFRX	0.00	3.64	4.33
2026-01-20	IFRX	0.00	3.64	4.33
2026-01-21	IFRX	0.00	3.64	4.33
2026-01-22	IFRX	0.00	3.64	4.33
2026-01-23	IFRX	0.00	3.64	4.33
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

3.64

Beta

1.47

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.2

Max Drawdown 5-Year %

-88.5

Target Price

10.3

P/E

Forward P/E

PEG

P/S

P/B

1.28

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

-0.67

EPS Next Y. (Est.)

-0.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.31

Return on Equity vs Sector %

-115.7

Return on Equity vs Industry %

-99.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.07

EBIT Estimation

-8.9

InflaRx N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 74

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

stock quote shares IFRX – InflaRx N.V. Stock Price stock today

news today IFRX – InflaRx N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch IFRX – InflaRx N.V. yahoo finance google finance

stock history IFRX – InflaRx N.V. invest stock market

stock prices IFRX premarket after hours

ticker IFRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IFRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y